CN103479671B - A kind of iron dextran compound oral liquid and preparation technology thereof - Google Patents
A kind of iron dextran compound oral liquid and preparation technology thereof Download PDFInfo
- Publication number
- CN103479671B CN103479671B CN201310350134.1A CN201310350134A CN103479671B CN 103479671 B CN103479671 B CN 103479671B CN 201310350134 A CN201310350134 A CN 201310350134A CN 103479671 B CN103479671 B CN 103479671B
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- iron dextran
- purified water
- corii asini
- colla corii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 21
- -1 iron dextran compound Chemical class 0.000 title claims abstract description 10
- 238000005516 engineering process Methods 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 28
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008213 purified water Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 108010052008 colla corii asini Proteins 0.000 claims abstract description 17
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003080 taurine Drugs 0.000 claims abstract description 14
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 10
- 229930006000 Sucrose Natural products 0.000 claims abstract description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 10
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 10
- 239000005720 sucrose Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000007502 anemia Diseases 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 208000002720 Malnutrition Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 210000002216 heart Anatomy 0.000 abstract description 2
- 230000001071 malnutrition Effects 0.000 abstract description 2
- 235000000824 malnutrition Nutrition 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 11
- 230000037396 body weight Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000824799 Canis lupus dingo Species 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of iron dextran compound oral liquid, this oral liquid is made up of the raw material of following weight proportion: iron dextran 20-40kg; Colla Corii Asini 1-5kg; Taurine 5-13kg; Sucrose 10-50kg; Benzoic acid 0.35kg; Purified Water q. s.The present invention also provides a kind of preparation technology of iron dextran compound oral liquid, comprises the following steps: A, get the Colla Corii Asini that purified water adds prescription amount, treats that Colla Corii Asini all dissolves; B, get the taurine that purified water adds prescription amount, make it dissolve completely; Mixed liquor in C, the iron dextran getting prescription amount and step B adds in the mixed liquor in the steps A prepared successively, makes its mix homogeneously; Oral liquid of the present invention is widely used in the iron deficiency anemia that chronic blood loss, malnutrition, period of development etc. cause, and also can be used as the auxiliary treatment of the anemic disorders such as surgery recovery, Liver and kidney, heart, skin.
Description
Technical field
The present invention relates to a kind of drug compound preparation, especially a kind of prevention, the iron dextran compound oral liquid for the treatment of house pet iron deficiency anemia and preparation technology of being used for.Belong to veterinary drug technical field.
Background technology
Ferrum is the requisite material of body synthetic hemoglobin, is also the ingredient of Myoglobin, cytochrome and some enzyme simultaneously.
Cause haemachrome to generate during iron deficiency to reduce, hemoglobin reduction in each erythrocyte, oxygen carrying capacity declines, and forms iron deficiency anemia; Current, along with living environment constantly worsen with cause of disease be tending towards complicated, infectious disease is walked crosswise, pet dog etc. occur that the probability of anemia increases, ferrum element etc. in the mode added body needing efficient, long-acting, low toxicity, to pregnant dog, aged dog, young dog etc. lose ferrum too much or the situation of increase in demand all need to supplement, but mostly be on the market oral with the form of ferrous sulfate or injection, weak curative effect, otherwise injection is inconvenient.We develop a kind of compound recipe iron supplement prescription iron dextran and Colla Corii Asini formed for this reason, and convenient oral, dosage are accurate, and curative effect is worked in coordination with, and reaches iron supplement requirement.
Summary of the invention
The problem to be solved in the present invention is to provide a kind of convenient oral, dosage is accurate, and curative effect is worked in coordination with, and reaches the iron dextran compound oral liquid of iron supplement requirement.
In order to solve the problem, the present invention by the following technical solutions:
A kind of iron dextran compound oral liquid, this oral liquid is made up of the raw material of following weight proportion: iron dextran 20-40kg; Colla Corii Asini 1-5kg; Taurine 5-13kg; Sucrose 10-50kg; Benzoic acid 0.35kg; Purified Water q. s.
Below the further optimization of the present invention to such scheme:
This oral liquid is made up of the raw material of following weight proportion: iron dextran 30kg; Colla Corii Asini 3kg; Taurine 9kg; Sucrose 30kg; Benzoic acid 0.35kg; Purified Water q. s.
Another kind of optimization:
This oral liquid is made up of the raw material of following weight proportion: iron dextran 20kg; Colla Corii Asini 1kg; Taurine 5kg; Sucrose 10kg; Benzoic acid 0.35kg; Purified Water q. s.
Another kind of optimization:
This oral liquid is made up of the raw material of following weight proportion: iron dextran 30kg; Colla Corii Asini 2kg; Taurine 7kg; Sucrose 20kg; Benzoic acid 0.35kg; Purified Water q. s.
Another kind of optimization:
This oral liquid is made up of the raw material of following weight proportion: iron dextran 40kg; Colla Corii Asini 4kg; Taurine 11kg; Sucrose 40kg; Benzoic acid 0.35kg; Purified Water q. s.
Another kind of optimization:
This oral liquid is made up of the raw material of following weight proportion: iron dextran 40kg; Colla Corii Asini 5kg; Taurine 13kg; Sucrose 50kg; Benzoic acid 0.35kg; Purified Water q. s.
In above-mentioned prescription:
1, iron dextran: the complex of dextran and ferrum is soluble iron.Ferrum is the component of hemoglobin in erythrocyte.During iron deficiency, erythrocyte synthetic hemoglobin amount reduces, and causes erythrocyte volume to diminish, and oxygen carrying capacity declines, and forms iron deficiency anemia.Oral this product can supplement ferrum element, corrects iron deficiency anemia.
2, Colla Corii Asini: YIN nourishing of enriching blood, moisturizes, hemostasis.For blood deficiency etc.
3, taurine: taurine prevents and treats iron deficiency anemia positive effect, it not only can promote that intestinal is to the absorption of ferrum, also can increase the stability of erythrocyte membrane.
4, sucrose: correctives.
5, benzoic acid: antiseptic.
6, purified water: excipient.
The present invention also provides a kind of preparation technology of iron dextran compound oral liquid, comprises the following steps:
A, get the Colla Corii Asini that 30L purified water adds prescription amount, heat while stirring, treat that Colla Corii Asini all dissolves;
B, get the taurine that 30L purified water adds prescription amount, make it dissolve completely;
Mixed liquor in C, the iron dextran getting prescription amount and step B adds in the mixed liquor in the steps A prepared successively, adds while stirring, makes its mix homogeneously;
D, add prescription amount the mixed liquor of sodium benzoate in step C in;
E, last, add to 300L standardize solution by purified water, subpackage.
Oral liquid of the present invention is widely used in the iron deficiency anemia that chronic blood loss, malnutrition, period of development etc. cause, trimester of pregnancy of adults and lactation period the female animal iron deficiency anemia that intake deficiency causes because needing iron to increase and postpartum anemia.Also can be used as the auxiliary treatment of the anemic disorders such as surgery recovery, Liver and kidney, heart, skin.General disease medication is once namely good, acts on long-acting; Application method is simple; Use by recommended dose, have no adverse reaction.
Below by specific embodiment, the invention will be further described, but the present invention not limited by following examples.
Detailed description of the invention
Embodiment, a kind of iron dextran compound oral liquid, this oral liquid is made up of the raw material of following weight proportion:
| Main Ingredients and Appearance | Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 |
| Iron dextran | 20kg | 30kg | 30kg | 40kg | 40kg |
| Colla Corii Asini | 1kg | 2kg | 3kg | 4kg | 5kg |
| Taurine | 5kg | 7kg | 9kg | 11kg | 13kg |
| Sucrose | 10kg | 20kg | 30kg | 40kg | 50kg |
| Benzoic acid | 0.35kg | 0.35kg | 0.35kg | 0.35kg | 0.35kg |
| Purified water | Add to 300L | Add to 300L | Add to 300L | Add to 300L | Add to 300L |
Because company is type of production company, facilitate company technique to transform, company's prescription all carries out with the pattern of producing greatly, lab scale is 10:1, and pilot scale is 10:5, and above prescription is pilot-scale experiment, prescription 1 ~ 5 is process of the test, finally filters out prescription 3 for best prescription and technique according to result of the test.
The present invention adopts best prescription 3, carries out following test:
This EXPERIMENTAL DESIGN: choose Qingdao, each two the medium-and-large-sized pet clinics in Beijing, dog field is supported as test site in Weifang two, test period 6 months by a definite date.Wherein Qingdao and each one of Beijing pet clinic carry out iron deficiency anemia test, other two are carried out postoperative and convalescence test, iron deficiency anemia test is carried out in the one domestic dog field in Weifang, and the test of Liver and kidney aspect is carried out in another domestic dog field, adds up to case 728 example, relate to kind of dog 19, random experiment, and set up blank, by specification respectively, carry out oral depending on body weight and the infection order of severity, observed and recorded result.
Therapeutic effect of the present invention is as follows: oral, twice on the one, a 2-4ml, one day twice, is used in conjunction 7 days or follows the doctor's advice; Please refer to following medication guide: the treatment 1, being applied to iron deficiency anemia: dog, cat: 1-3ml/ time, twice on the one.2, Post operation or other diseases convalescence: twice on the one, a 2-4ml, according to the state of an illness, body weight suitably increases and reduction.3, liver, renal anemia disease auxiliary treatment a: twice-daily, a 2-4ml, according to the state of an illness, body weight suitably increases and reduction.4, old dog cat heart disease auxiliary treatment: once-a-day, a 1-2ml, according to the state of an illness, body weight suitably increases and reduction.5, dermatitis, by hair slightly disorderly: once-a-day, a 1-2ml, according to the state of an illness, body weight suitably increases and reduction.
Result of the test: form 2 (unit: head)
Observed and recorded result after 7 days, effective percentage 100%, cure rate is up to more than 90%, average cure rate 92.98%, other cases are also obviously improved, owing in test specifically not distinguishing sex and kind, after being diagnosis, random medication, can show thus, evident in efficacy.
Points for attention: 1, should use after practising veterinarian is diagnosed as anemia, and should hemogram be made regular check at treatments period.2, following situations is cautious use of: gastroduodenal ulcer; Ulcerative enteritis.3, as overdose or occur serious adverse reaction, please seek medical advice immediately.
For explaining, above-described embodiment illustrates that inventive concept of the present invention and reality use, all changes utilizing this design and actual use the present invention to be carried out to unsubstantiality, all should fall into protection scope of the present invention.
Claims (1)
1. a preparation technology for iron dextran compound oral liquid, this oral liquid is made up of the raw material of following weight proportion: iron dextran 30kg; Colla Corii Asini 3kg; Taurine 9kg; Sucrose 30kg; Benzoic acid 0.35kg; Purified Water q. s;
Preparation technology comprises the following steps:
A, get the Colla Corii Asini that 30L purified water adds recipe quantity, heat while stirring, treat that Colla Corii Asini all dissolves;
B, get the taurine that 30L purified water adds recipe quantity, make it dissolve completely;
Mixed liquor in C, the iron dextran getting recipe quantity and step B adds in the mixed liquor in the steps A prepared successively, adds while stirring, makes its mix homogeneously;
D, add recipe quantity the mixed liquor of sodium benzoate in step C in;
E, last, add to 300L standardize solution by purified water, subpackage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310350134.1A CN103479671B (en) | 2013-08-13 | 2013-08-13 | A kind of iron dextran compound oral liquid and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310350134.1A CN103479671B (en) | 2013-08-13 | 2013-08-13 | A kind of iron dextran compound oral liquid and preparation technology thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479671A CN103479671A (en) | 2014-01-01 |
| CN103479671B true CN103479671B (en) | 2015-09-09 |
Family
ID=49820492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310350134.1A Active CN103479671B (en) | 2013-08-13 | 2013-08-13 | A kind of iron dextran compound oral liquid and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479671B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106361849A (en) * | 2016-08-31 | 2017-02-01 | 天津市中升挑战生物科技有限公司 | Oral liquid capable of supplementing iron for beasts and preparing method thereof |
-
2013
- 2013-08-13 CN CN201310350134.1A patent/CN103479671B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 牛磺酸对大鼠缺铁性贫血的影响;田玉慧等;《基础医学与临床》;19911231;第11卷(第1期);第51-53页 * |
| 益血生冲剂与右旋糖酐铁治疗缺铁性贫血疗效分析;胡延生等;《现代诊断与治疗》;20041231;第15卷(第4期);第226-227页 * |
| 阿胶铁口服液改善营养性贫血的功能研究;朱金芳等;《新疆医科大学学报》;20070831;第30卷(第8期);第797-799页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479671A (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103479671B (en) | A kind of iron dextran compound oral liquid and preparation technology thereof | |
| CN107417556A (en) | L aspartase calciums and preparation method thereof | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN101496811A (en) | Soluble and stable tilmicosin composition | |
| CN103816166B (en) | Compound doxycycline hydrochloride injection for animals, and its preparation method | |
| CN103169652B (en) | Veterinary alkaline lincomycin injection as well as preparation method and use thereof | |
| CN103989673A (en) | Compound amino acid injection for children | |
| CN101884642A (en) | Compound emulsifiable paste for treating acne and preparation method thereof | |
| CN103126982A (en) | Novel veterinary medicament meglumine enrofloxacin injection and preparation method thereof | |
| CN103655593B (en) | Composite medicine preparation for prevention and treatment of bacterium and virus polyinfection diseases of livestock as well as preparation method and application thereof | |
| CN103877115B (en) | A kind of compound vitamin composition, its pharmaceutical preparation and application | |
| CN103083349A (en) | Compound fluconazole gel for pets and preparation process thereof | |
| CN105125484A (en) | Painless doxycycline injection and preparation method thereof | |
| CN103860474A (en) | Doxycycline soluble powder production method | |
| CN103432136A (en) | Composition for treating salpingitis of chicken and preparation method of composition | |
| CN104586757A (en) | Veterinary enrofloxacin injection and preparation method thereof | |
| CN112300299A (en) | Preparation method and application of zinc and calcium polysaccharide complex | |
| CN104721133B (en) | A kind of terramycin preparation and preparation method | |
| CN103394021A (en) | Compound medicament for treating proventriculitis and gizzard erosion of poultry and preparation method thereof | |
| CN103301138B (en) | A kind of preparation method of compound oxybiotic injection | |
| CN102973577B (en) | Compound sodium sulfaquinoxaline composition for treating coccidiosis in young rabbits, and preparation method thereof | |
| US3047464A (en) | Gold-isoquinoline-yohimbine complex for rheumatic diseases | |
| CN105560248A (en) | Pharmaceutical composition for treating fungal infection and preparing method and application thereof | |
| CN104771757A (en) | Compound preparation for treating broiler proventriculitis | |
| CN104666307B (en) | Natural drug monomer compound preparation for animals and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Iron dextran compound oral liquid and preparation technology thereof Effective date of registration: 20180424 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018980000053 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181017 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018980000053 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Iron dextran compound oral liquid and preparation technology thereof Effective date of registration: 20181105 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018980000208 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191107 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018980000208 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Iron dextran compound oral liquid and preparation technology thereof Effective date of registration: 20191213 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2019370000120 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210122 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2019370000120 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210204 Address after: 262100 C12, Chang'an Industrial Park, Cuishan street, Xin'an street, Anqiu City, Weifang City, Shandong Province Patentee after: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 262100 Lijiabu, Dawenhe Tourism Development Zone, south of Qingyun Mountain, Anqiu City, Weifang City, Shandong Province Patentee before: WEIFANG FUBANG PHARMACEUTICAL Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Iron dextran compound oral liquid and its preparation process Effective date of registration: 20220328 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2022980003376 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230324 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2022980003376 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound oral liquid of iron dextran and its preparation process Effective date of registration: 20230329 Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2023980036422 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2023980036422 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound oral solution of iron dextran and its preparation process Granted publication date: 20150909 Pledgee: Anqiu Shandong rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG YAHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2024980009808 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |